Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange

Journal of Clinical Apheresis

Volumn 30, Issue 5, 2015, Pages 308-310

  Sullivan, Matthew R ^a   Danilov, Alexey V ^a   Lansigan, Frederick ^a   Dunbar, Nancy M ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

carfilzomib; multiple myeloma; plasma exchange; thrombotic microangiopathy

Indexed keywords

CARFILZOMIB; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

AGED; ANEMIA; ARTICLE; CASE REPORT; CONFUSION; ERYTHROCYTE TRANSFUSION; FALLING; FLAPPING TREMOR; HUMAN; KIDNEY FAILURE; LEG EDEMA; MALE; MULTIPLE MYELOMA; PLASMAPHERESIS; SKIN BRUISING; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISSEMINATED INTRAVASCULAR COAGULATION; DYSKINESIA, DRUG-INDUCED; HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC MICROANGIOPATHIES; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTIONS;

ADAM PROTEINS; AGED; CONFUSION; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; DISSEMINATED INTRAVASCULAR COAGULATION; DYSKINESIA, DRUG-INDUCED; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MULTIPLE MYELOMA; OLIGOPEPTIDES; PLASMA EXCHANGE; PROTEASOME INHIBITORS; THROMBOTIC MICROANGIOPATHIES; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTIONS;

EID: 84944323229     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21371     Document Type: Article

References (9)

1. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The sixth special issue. J Clin Apher 2013; 28: 145-284.
2. George JN,. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.
3. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
4. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL,. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-799.
5. Kortuem KM, Stewart AK,. Carfilzomib. Blood 2013; 121: 893-897.
6. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S,. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
7. Salmenniemi U, Remes K,. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 2012; 4: e13.
8. Yao H, Monge M, Renou M, Lecaque C, Jaureguy M, Presne C, Makdassi R, Choukroun G,. Thrombotic thrombocytopenic purpura due to anti-ADAMTS13 antibodies in multiple myeloma. Clin Nephrol 2012; 119.
9. Munoz J, Hughes A,. Thrombotic thrombocytopenic purpura after autologous peripheral stem cell transplantation. Blood 2012; 119: 5620.